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Abstract
Primary biliary cirrhosis (PBC) is a chronic cholestatic disorder characterised by an immunological, and often granulomatous, attack on
bile ducts leading to fibrosis, cirrhosis, liver failure and death. Animal and human studies suggest that oxidant stress plays a key role in
progression of other liver diseases, but no comprehensive investigation has been performed previously in PBC. A wide range of lipid
peroxidation and antioxidant markers were measured in the blood and urine of 41 patients with histologically confirmed PBC. Lipid
peroxidation markers were significantly elevated [plasma and urinary 8-isoprostane, P< 0.001; plasma malondialdehyde (MDA), P= 0.007]
compared to age- and sex-matched controls. The most striking antioxidant depletion occurred with plasma total glutathione where levels were
significantly reduced (30% of controls). Total serum antioxidant levels were decreased (P= 0.013) and serum selenium and vitamin A were
also lower (both P< 0.001); vitamins C and E were normal. Most patients had early disease biochemically and were Child-Pugh grade A.
Urinary 8-isoprostane correlated positively with Ludwig stage and markers of hepatic injury and cholestasis. This study clearly demonstrates
that oxidant stress, as reflected in a comprehensive spectrum of lipid peroxidation and antioxidant markers, is a significant feature of early-
stage PBC.
D 2002 Elsevier Science B.V. All rights reserved.
Keywords: Primary biliary cirrhosis; Oxidant stress; Lipid peroxidation; Antioxidant
1. Introduction
Primary biliary cirrhosis (PBC), predominantly affecting
middle-aged women, is a chronic cholestatic disorder which
has a prevalence of 20–150 cases per 100,000 population in
the Western World. The disease is characterised by an
immunological attack on medium size (interlobular) bile
ducts; this produces cholestasis with retention of copper and
toxic primary bile acids, followed by the development of
fibrosis. The natural history of the disease and its histolog-
ical evolution have been well documented [1] and whilst a
number of drugs, including ursodeoxycholic acid [2], col-
chicine [3–6] and corticosteroids [7], may modify the
course of the disease, none is curative. PBC therefore
remains a major indication for liver transplantation.
The pathophysiological mechanisms underlying progres-
sion from the initial autoimmune attack to the development
of fibrosis and, ultimately, cirrhosis and liver failure in PBC
are poorly understood, but recent work indicates that gen-
eration of reactive oxygen species (ROS) such as the
superoxide anion and the hydroxyl radical may play a role.
Oxidant stress has been demonstrated in animal models of
acute and chronic liver disease and, in particular, in a rat
model of cholestasis, induced by bile duct ligation [8–10].
The authors suggest that ROS were generated by inflam-
matory processes and possibly by endotoxin or bile acids;
copper retention in cholestasis may also play a part as
demonstrated in a rat model of copper accumulation [11].
Oxidant stress has also been observed in a variety of human
liver disorders, including chronic viral hepatitis [12,13],
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alcoholic liver disease [14], Wilson’s disease and haemach-
romatosis [15]. In PBC, one histological study in liver
biopsies from five patients demonstrated the presence of
malondialdehyde (MDA) and 4-hydroxynonenal (HNE)
adducts, major metabolites of lipid peroxidation [16]. In a
more recent and larger study, HNE protein adducts have
been detected in hepatocytes preferentially located around
the portal tracts as well as in the cytoplasm of damaged, but
also intact, biliary cells [17]. Elevated levels of Mn-super-
oxide dismutase have been found, and immunostaining of
liver biopsies has shown increased expression of this protein
in damaged epithelial cells of interlobular bile ducts, bile
ductules and degenerated hepatocytes. This finding suggests
that free radicals, including the superoxide anion, may be
involved in the pathogenesis of the disease [18]. Micro-
nutrient studies of individual vitamins and selenium in liver
disease have shown some deficiencies in small numbers of
PBC patients but these individual factors were examined in
a dietary context rather than as a panel of markers of oxidant
stress [19–21].
Oxidant stress arises when there is an imbalance between
radical-generating and radical-scavenging activity; it may
therefore cause an increase in the formation of oxidation
products and a decrease or depletion of endogenous anti-
oxidant protection mechanisms. Oxidative damage of lipids
leads to the generation of MDA and 8-isoprostane. MDA is
the end product of peroxidative decomposition of polyenic
fatty acids and, in the experimental animal, the level in
tissues [10] is indicative of the extent of lipid peroxidation.
Whilst lipid peroxidation is traditionally assessed by meas-
urement of MDA, a more sensitive measure can be provided
by determination of 8-isoprostane, a product of arachidonic
acid peroxidation [22]. Individual antioxidant components
include vitamins A, C and E, and selenium, an essential co-
factor of glutathione peroxidase. Glutathione is a major
component of the antioxidant system and synthesis in, and
efflux from, the liver is the main source of plasma gluta-
thione [23]. However, previous work has suggested that
glutathione metabolism is disturbed only in late stage,
decompensated hepatic disorders [24]. In the present study,
in addition to the above markers, we have also measured
total antioxidant capacity, which reflects the effective sum
of all cooperative chain-breaking antioxidants.
To date, no comprehensive investigation of oxidant stress
in PBC has been published. The present study is designed to
determine, first, whether oxidant stress occurs in this disease
by measuring, in blood and urine, a wide spectrum of
markers reflecting both pro- and antioxidant facets of the
process. Second, we wish to determine whether this process
occurs in early stage PBC and may therefore play a
pathophysiological role in the early progression of this
disease or, alternatively, is confined to late stage disease
when it presumably reflects major, but nonspecific, distur-
bances in hepatic metabolism. Finally, we wish to elucidate
the mechanisms underlying this pathophysiology by assess-
ing the relationship between oxidant stress and markers of
fibrosis and cholestasis. For the former we have measured
serum type III procollagen peptide (PIIINP), which we have
previously shown to accurately reflect hepatic fibrogenesis
and prognosis in PBC, and for the latter, serum bilirubin,
which is of major prognostic value in this disease as well as
serum bile acids, the most sensitive indicator of cholestasis,
in addition to assessment of copper binding protein by
orcein, a surrogate histological marker of cholestasis.
2. Materials and methods
2.1. Study groups
The study was approved by the Central Manchester
Health Authority Research Ethics Committee and all
patients gave written informed consent. All subjects were
nonsmokers, took no vitamin supplements and had a normal
nutritional status. All PBC patients (n = 41) fulfilled conven-
tional diagnostic criteria, with a raised serum alkaline
phosphatase (ALP), a positive anti-mitochondrial antibody
test and a liver biopsy diagnostic of, or compatible with this
diagnosis [4]. Pruritis was present in 34% of patients whilst
the other 66% had few, if any, symptoms directly referable
to the disease. No patient had received ursodeoxycholic
acid, colchicine or corticosteroids for at least 3 months. As
the PBC patients were all Caucasian and predominantly
older females, care was taken to ensure that patient and
control groups were age-, sex- and race-matched (control
group n = 34, 7h 27U, age = 53.1F11.9 years, range 37–79
years: PBC group n = 41, 4 h 37U, age = 57.9F 9.0 years,
range 37–72 years). Disease severity was assessed bio-
chemically (serum bilirubin [25]), and by Child-Pugh grade
[26].
2.2. Liver biopsy
A subset of PBC patients (n = 20) had been biopsied
within 9 months of entry to this study (mean time = 1.8
months). Needle liver biopsies were fixed in formalin and
stained with haematoxylin/eosin, orcein and Gordon and
Sweets’ reticulin. All biopsies were assessed blindly by a
single histopathologist for Ludwig stage [27] and for the
presence of orcein staining (for the detection of copper
binding protein, a surrogate marker for histological choles-
tasis) as well as for the presence and number of granuloma
in each biopsy.
2.3. Specimen processing
Blood and urine samples were collected after overnight
fasting. For measurement of MDA and 8-isoprostane, blood
was collected into ice-cold tubes containing EDTA (1 mg/
ml) and GSH (1 mg/ml) and, after centrifugation (800 g,
10 min), the plasma was protected from oxidation during
storage by addition of the chain-breaking antioxidant buty-
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lated hydroxytoluene (BHT) (200 Ag/ml). Urine was pro-
tected by addition of indomethacin (0.001% w/v) to prevent
in vitro formation of prostanoids due to any leucocyte
contamination [28]. Serum (1 ml) was added to 1-ml ice-
cold 10% (w/v) trichloroacetic acid and, after centrifugation
(3300 g, 20 min), the deproteinated sample was used for
vitamin C determination. Whole blood for glutathione assay
was kept on ice and analysed on the morning of collection.
All other samples were stored at  70 jC prior to assay.
2.4. Analytical procedures
2.4.1. 8-Isoprostane
Plasma or urine (0.5 ml) was mixed with 10-Al [3H]-
prostaglandin F2a (NEN, Boston, MA; ca. 20000 dpm;
added to estimate recovery), 3-Al BHT (10% w/v in meth-
anol) and 2-ml methanol. After standing on ice for 5 min,
precipitated protein was removed by centrifugation
(1200 g, 10 min) and the pH of the supernatant adjusted
to below 4.0 by addition of 0.3 M sodium phosphate and 1
M HCl. Solid phase extraction [28] was carried out on C18
BondElut (500 mg; Varian, Harbor City, CA). Extracts were
reconstituted in 1-ml 0.1 M phosphate buffer pH 7.4
containing 1% BSA and 0.02% (w/v) BHT. After taking
0.25 ml for [3H] counting, 50-Al aliquots were assayed for
8-isoprostane using an enzyme-linked immunoassay kit
(Cayman Chemicals, Ann Arbor, MI). Urinary creatinine
was estimated using an alkaline picrate solution [29].
2.4.2. MDA
This was determined in serum by the 2-thiobarbituric
acid reactive substances (TBARS) method. Precipitation of
serum lipoproteins using a phosphotungstic acid–sulfuric
acid system was performed to ensure removal of interfering
water-soluble substances [30]. 2-Thio-barbituric acid (TBA)
was added to the precipitate and, after boiling for 60 min,
the red pigment generated was extracted with butan-1-ol and
measured fluorimetrically. 1,1,3,3,-Tetraethoxypropane
(Sigma-Aldrich Company Ltd., Poole, Dorset, UK) was
used as a standard. As the TBARS method proved relatively
insensitive for MDA measurement in acid-precipitated
serum, an improved and more reproducible fluorimetric
method [31] was also employed using 1,3-diethyl-2-thio-
barbituric acid (DETBA) to measure MDA in whole serum.
2.4.3. Total antioxidant capacity
This was measured in whole and protein-free serum by
an enhanced chemiluminescent technique [32]. A stable
light output was generated by mixing 200-Al luminol-based
reagent (Supersignal CL-HRP Substrate System, Pierce &
Warriner, Chester, UK) with 2.3-ml water and 25-Al anti-
mouse IgG horse radish peroxidase-linked whole antibody
from sheep (1:250; Sigma-Aldrich). Addition of 50-Al
whole serum (diluted 1:14 with distilled water), protein-free
serum (1: 5) or Trolox standard (50 AM; Sigma-Aldrich)
resulted in depression of the signal for a period of time
which is proportional to the antioxidant concentration.
Results were expressed as trolox equivalents, assuming a
stoichiometric factor of 2. Serum was deproteinated by
centrifugation through an Amicon Centrifreek Microparti-
tion System (Millipore Corporation, Bedford, MA).
2.4.4. Selenium
A simple single-tube fluorimetric assay was employed
[33]. Serum or selenium standard (100 Al) (500 Ag/l; Merck,
Lutterworth, Leics) was digested with 100 Al perchloric acid
(60%v/v) + 0.4 ml nitric acid (69%v/v) for 90 min at 190 jC
to free selenium from organic materials. The Se(VI) pro-
duced was then reduced to Se(IV) by incubation with 0.5-ml
hydrochloric acid (37%v/v) at 150 jC for a further 30 min.
Following incubation with 0.5-ml 2,3-diaminonaphthale-
neHCl (Sigma-Aldrich; 0.1% w/v) and 2-ml EDTA (2.5
mM) at 60 jC for 30 min, the resulting fluorophore was
extracted into 1.3-ml cyclohexane and its fluorescence
measured at kex = 373 nm, kem = 515 nm.
2.4.5. Vitamin A
Methanol (1.4 ml) +water (0.28 ml) was added to 100-Al
serum or all-trans-retinol acetate standard (Sigma-Aldrich;
15 AM in cyclohexane) followed by 1.4-ml cyclohexane
[34]. After centrifugation (1200 g, 10 min) to separate
phases, fluorescence was measured at kex = 323 nm,
kem = 470 nm in the upper layer.
2.4.6. Vitamin C
2,4-Dinitrophenylhydrazine (0.1 ml) (3% w/v; Sigma-
Aldrich)/thiourea (0.4% w/v)/copper sulfate (0.05% w/v) in
4.5M sulfuric acid was incubated at 37 jC for 3 h with 0.5-ml
deproteinated serum or ascorbic acid standard (20 mg/l in 5%
(w/v) TCA) [35]. After addition of 0.75-ml ice-cold sulfuric
acid (65% v/v) and incubation for a further 30 min at RT,
absorbance was measured at k = 500 nm.
2.4.7. Vitamin E
Pyrogallol (0.7 ml) (Sigma-Aldrich; 2% w/v in methanol)
and 105-Al saturated potassium hydroxide were incubated at
70 jC for 30 min with 0.35-ml serum or a-tocopherol
standard (Sigma-Aldrich; 50 mg/l in methanol) [36]. Water
(0.35 ml) and hexane (1.4 ml) were added and, after
centrifugation (1200 g, 10 min) to separate phases, the
fluorescence was measured at kex = 287 nm, kem = 321 nm in
the upper layer.
2.4.8. Glutathione
Three distinct measurements were performed: (1) Total
glutathione, the sum of reduced (GSH) and oxidised gluta-
thione (GSSG) in fresh whole blood. Ten microliters was
haemolysed in 3.99-ml ice-cold phosphate-EDTA buffer,
pH 7.5. (2) Total glutathione (GSH+GSSG) in plasma.
Fresh whole blood (0.6 ml) was added to 0.6 ml 5,5V-dithio-
bis(2-nitrobenzoic acid) (DTNB) (10 mM in ice-cold phos-
phate-EDTA buffer, pH 7.5), and centrifuged (1200 g, 6
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min) immediately. By adding the reagent directly, DTNB
reacts rapidly with free sulfydryl groups and prevents
oxidation of GSH during sample preparation. (3) GSSG in
plasma. Fresh whole blood (0.6 ml) was added to 0.6 ml 10
mM N-ethyl-maleimide (NEM) in phosphate-EDTA buffer
pH 6.5, and centrifuged as before. NEM chemically traps
GSH and prevents autooxidation to GSSG. NEM was
removed by solid phase extraction prior to assay.
The reduction of DTNB by NADPH was catalysed by
GSH or GSSG and glutathione reductase and the resulting
absorbance measured at k = 412 nm [37].
2.4.9. PIIINP
This serum marker of hepatic fibrogenic activity was
measured using the Type III procollagen intact PIIINP
radioimmunoassay (Orion Diagnostica, Espoo, Finland).
2.4.10. Other serum markers
Aspartate transaminase (AST), alanine transaminase
(ALT), alkaline phosphatase (ALP), g-glutamyl transferase
(gGT), total protein, albumin, bilirubin, urate, cholesterol,
high density lipoprotein (HDL), triglycerides and prothrom-
bin index were determined by standard automated techni-
ques. Total serum bile acid concentration, the most sensitive
indicator of cholestasis, was measured spectrophotometri-
cally using the Enzabile test kit (Bio-Stat Diagnostic Sys-
tems, Stockport, UK).
2.5. Statistics
Since much of the data were not normally distributed, all
values were expressed as medians and nonparametric sta-
tistics were employed. Differences between groups were
assessed using the Mann–Whitney U-test. The significance
of correlations between parameters was assessed using the
Spearman rank test. For all analyses, a P-value of < 0.05
was considered to be statistically significant.
3. Results
The great majority of patients were shown to have early
stage disease (Child-Pugh grade A); only two patients were
grade B (both with a score of 9 points). The concentrations,
in PBC and control groups, of all biochemical markers used
in this study are shown in Table 1.
8-Isoprostane was significantly elevated in both urine
and plasma. Although MDA by TBARS was raised in the
PBC patients, this increase was not significant. In contrast,
when MDAwas measured by the more sensitive 1,3-diethyl-
2-thio-barbituric acid reactive substances (DETBARS)
method, PBC patients showed a significant elevation. Uri-
nary 8-isoprostane and MDA (by DETBARS) were the two
lipid peroxidation marker assays of choice (Fig. 1a and b).
Antioxidant status was compromised in PBC, with sev-
eral important components of the antioxidant defence mech-
anism being significantly decreased. The total antioxidant
capacity in whole serum was significantly reduced in PBC
patients (Fig. 1c), but in protein-free serum was normal,
suggesting that protein-bound components make an impor-
tant contribution. Total glutathione (GSH+GSSG) in whole
blood, a measure of intracellular antioxidant reserve, was
not significantly different from the control group. The most
striking antioxidant depletion occurred with total gluta-
thione in plasma, where levels were significantly reduced
to about 30% of control values (Fig. 1d). Plasma GSSG,
expressed as a percentage of total plasma glutathione, was
normal in the PBC group. Individual antioxidants were also
shown to be affected; serum levels of selenium and vitamin
A were significantly diminished (Fig. 1e and f). In contrast,
serum levels of vitamins C and E and urate were normal.
When vitamin E was expressed as a ratio compared to lipid
(vitamin E/cholesterol, vitamin E/HDL and vitamin E/TG;
results not shown), the ratios were also normal.
Table 1
Oxidant stress in control and PBC groups: markers of lipid peroxidation,
antioxidant status, hepatic fibrogenesis, hepatic function and other
biochemical parameters
Assay Control PBC P
8-Isoprostane (u) 0.33 0.84 < 0.001
8-Isoprostane (p) 15.5 38.3 < 0.001
MDA (TBARS) 2.05 2.37 ns
MDA (DETBARS) 2.49 2.98 0.007
Total antioxidant (ws) 0.95 0.86 0.013
Total antioxidant (pfs) 0.45 0.42 ns
Total glutathione (wb) 1.42 1.39 ns
Total glutathione (p) 2.65 0.79 < 0.001
GSSG/(GSH+GSSG) 9.6 8.2 ns
Selenium 99.8 87.8 < 0.001
Vitamin A 3.61 2.52 < 0.001
Vitamin C 17.9 15.0 ns
Vitamin E 14.4 13.7 ns
PIIINP 2.80 5.40 < 0.001
AST 21 68 < 0.001
ALT 17 68 < 0.001
ALP 170 838 < 0.001
gGT 16 340 < 0.001
Total protein 78 82 0.003
Albumin 46 42 < 0.001
Bilirubin 10 14.5 0.005
Urate 0.26 0.26 ns
Cholesterol 6.25 6.10 ns
HDL 1.58 1.50 ns
TG 1.35 1.10 ns
Prothrombin index 0.89 0.92 ns
Total bile acids 3 10 < 0.001
Values shown as medians. P values derived by the Mann–Whitney test.
ns = not significant. Units were expressed as follows: urinary 8-isoprostane in
ng/g creatinine; plasma 8-isoprostane in ng/l; MDA (TBARS and
DETBARS), total glutathione (p), vitamin A, total bile acids and bilirubin
in Amol/l; total glutathione (wb), urate, cholesterol, HDL and TG in mmol/l;
total antioxidant (ws and pfs) in Amol/l trolox equivalents; GSSG/
(GSH+GSSG) 100 as %; selenium and PIIINP in Ag/l; vitamins C and
E in mg/l; total protein and albumin in g/l; AST, ALT, ALP and gGT in U/l.
u= urine, p = plasma, ws =whole serum, pfs = protein-free serum,wb =whole
blood.
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Serum PIIINP was significantly elevated in PBC patients,
confirming that, as we have previously demonstrated, hep-
atic fibrogenesis is a prominent feature even in the early
stages of this disease [38]. All conventional serum enzyme
markers of hepatic injury (AST, ALT, ALP and gGT) were
also significantly raised in the PBC group. Albumin was
reduced significantly in the PBC group whilst, in contrast,
total protein was significantly increased, reflecting increased
serum globulin levels characteristically found in this puta-
tive autoimmune disorder. Although serum bilirubin was
significantly higher in the PBC group than in the controls,
almost all values were within the normal range and the great
majority of patients had early disease; only four patients had
serum bilirubin levels >34 Amol/l, the level above which
patients in general enter an accelerated phase of disease
progression [25]. The prothrombin index was normal and all
clotting times were within 2 s of normal. Median levels of
cholesterol, HDL and triglycerides were no different com-
pared to controls. In contrast, serum total bile acids were
significantly elevated in PBC patients, with a median level
threefold higher than the normal group.
In the patient group, the most sensitive indicator of lipid
peroxidation, urinary 8-isoprostane, correlated positively
with markers of hepatocellular injury (AST: r = 0.57,
P< 0.001; ALT: r = 0.39, P= 0.013), and cholestasis (ALP:
r = 0.41, P= 0.008; bilirubin: r= 0.38, P= 0.018; total bile
acids r = 0.47, P= 0.0024) and negatively with vitamin A
(r = 0.40, P= 0.011). MDA, measured by the DETBARS
assay, correlated similarly with markers of hepatocellular
injury and cholestasis. The two methods used to measure
MDA correlated significantly (r = 0.46, P= 0.003), but the
poor reproducibility of the TBARS method resulted in a
lower than expected r value. Serum selenium concentrations
showed a highly significant, positive correlation with albu-
min (r = 0.56, P< 0.001). The important contribution of the
chain-breaking antioxidant urate to the total antioxidant
capacity was reflected in excellent correlations between the
two parameters in both whole (r = 0.90, P< 0.001) and
protein-free serum (r = 0.89, P< 0.001).
In the patient group in whom recent liver histology was
available, Ludwig stage (Fig. 2) correlated positively with
urinary 8-isoprostane (r = 0.45, P= 0.045), with serum
Fig. 1. Key markers of lipid peroxidation and antioxidant status in control and PBC groups. Medians are indicated. P values derived by the Mann–Whitney test.
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PIIINP (r= 0.61,P= 0.004) andwith total bile acids (r= 0.57,
P= 0.009). Granuloma score correlated negatively with uri-
nary 8-isoprostane (r = 0.45,P= 0.048) and positively with
selenium (r = 0.45, P= 0.048). Orcein staining correlated
positively with urinary 8-isoprostane (r= 0.59, P= 0.006),
PIIINP (r= 0.50, P= 0.026) and total bile acids (r = 0.60,
P = 0.005) and negatively with vitamin A (r = 0.49,
P= 0.026).
4. Discussion
Oxidant stress is now a recognised feature of chronic
liver disease and, in PBC, a number of mechanisms can be
envisaged by which excess free radical activity can contrib-
ute to both initial bile duct damage and later progression to
cirrhosis and death. Inflammation is a common and early
feature of PBC and invading macrophages will generate
ROS, such as superoxide and hydrogen peroxide, leading to
lipid peroxidation [39]. Cholestasis, also a major feature of
PBC, leads to accumulation of bile acids and hepatic copper,
both of which can lead to generation of free radicals [15,40].
Hepatic decompensation in late stage disease [24] can itself
lead to further generation of free radicals.
The present study complements recent publications
[16,17] which have demonstrated, immunohistochemically,
the presence of enhanced lipid peroxidation in the bile ducts
and hepatocytes of PBC patients. Although, as we have
previously discussed [13], the assessment of oxidant stress
in blood and urine has limitations, our work supports these
immunohistochemical findings. We have assessed a broad
spectrum of markers reflecting different facets of the disease
process and oxidative and antioxidant activity. This
approach may give an insight concerning the importance
of the various mechanisms proposed.
Oxidative damage to lipids has traditionally been assessed
using the TBARS assay, which detects MDA, a peroxidation
product of polyunsaturated fatty acids. However, we have
previously demonstrated in hepatitis C [13] that urinary 8-
isoprostane, a free radical mediated product of arachidonic
acid peroxidation, is more sensitive. This has been confirmed
in the present study, where plasma and urinary 8-isoprostane
levels were significantly elevated, being two- to threefold
higher in the PBC group than in controls. Although MDA,
measured by the DETBARS method, was also significantly
increased, median levels were only 20% higher than the
control group. Elevated levels of 8-isoprostanes have been
demonstrated in the plasma and urine of smokers, who are
known to be under oxidant stress [41] and in the bile [42] and
urine [43] following carbon tetrachloride-induced liver injury
in the rat.
The antioxidant defence system includes a wide range of
enzymatic and nonenzymatic components [44] including
some serum markers of prognostic value in PBC (e.g.
albumin and bilirubin). The total antioxidant assay employed
provides a global assessment of the body’s antioxidant
reserve, in both the aqueous and lipid phases. It reflects a
complex array of factors, such as antioxidant turnover rates
in the tissues, recycling of ascorbic acid and tocopherol, and
production of bilirubin. Urate, probably the most important
Fig. 2. Correlation of urinary 8-isoprostane, PIIINP and total bile acids with
Ludwig stage in PBC patients. P and r values were derived by the Spearman
test.
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single factor in determining total antioxidant capacity [45],
binds iron and copper and scavenges hydroxyl and peroxy
radicals. Our results show that total antioxidant capacity in
whole serum is reduced in PBC despite the fact that urate
levels are unchanged. The total antioxidant capacity in
protein-free serum was also unchanged. Therefore, the
observed fall in whole serum total antioxidant capacity
probably results from a decrease in protein-bound factors
such as –SH groups on proteins, vitamin E residing in the
lipoprotein moiety and bilirubin located on albumin. How-
ever, in the PBC group, whilst albumin was reduced, vitamin
E was unchanged and bilirubin and total protein were
increased.
Selenium is an essential co-factor of glutathione perox-
idase, the enzyme responsible for catalyzing the reduction of
hydroperoxides in the presence of glutathione. In both
alcoholic and nonalcoholic liver disease, selenium levels
are reduced in the liver and serum, but not in urine [19]. Burk
et al. [46] showed that plasma selenium in a variety of liver
diseases declined in proportion to the severity of the cirrhotic
condition as indicated by the Child’s grade. However, as
plasma glutathione peroxidase actually increased, patients
with cirrhosis do not appear to have functional selenium
deficiency. Selenium levels in our PBC group were slightly
but significantly reduced, consistent with these earlier obser-
vations, and reflecting the early stage of the disease.
As well as being a major component of the aerobic
antioxidant system, glutathione plays a central role in such
diverse biological processes as the detoxification of xeno-
biotics, maintenance of protein thiol levels and amino acid
transport across membranes [23]. Plasma glutathione is
known to reflect intrahepatic glutathione concentration, and
is an index of the balance between glutathione efflux from
the liver and uptake by the kidney [47]. In our PBC group,
there was a striking reduction in plasma total glutathione
(GSH+GSSG), suggesting that intrahepatic reserves were
severely compromised. Plasma oxidized glutathione (GSSG)
arises from both hepatic and extrahepatic sites, and provides
a sensitive index of whole-body oxidant stress. However, as
no increase in the plasma GSSG/(GSH+GSSG) ratio was
observed, it must be assumed that the glutathione redox cycle
is working efficiently in our PBC group and that GSSG is
being recycled to GSH by NADPH/glutathione reductase.
These results are in agreement with observations using a rat,
bile-duct ligation model [10], where plasma total glutathione
was significantly reduced, but the GSSG/(GSH +GSSG)
ratio was found to be unchanged. In our experience, high
GSSG/(GSH+GSSG) ratios only occur in cirrhotic patients
with severe disruption of hepatic metabolism (unpublished
results). A recent publication [48] found that a marked
reduction in the expression of glutathione-S-transferase
(reflecting reduced intracellular glutathione) was linked to
increased perinuclear expression of HNE in the damaged bile
ducts of PBC patients.
A predictable consequence of cholestasis is malabsorption
of fat-soluble factors (vitamins A, D, E and K) and other free
radical scavengers such as carotenoids. Retinol, a-tocopherol
and total carotenoids have been shown to be reduced in PBC,
but plasma levels were not affected by the histological stage
in one study [49]. Kaplan et al. [20] also found vitamin A
commonly decreased in PBC but, in contrast to our study,
decreased levels correlated with both the histological stage
and clinical severity of disease. Vitamin A was also signifi-
cantly reduced in our PBC group but no correlation was
found with Ludwig stage. Malabsorption is unlikely to
explain the low vitamin A levels found in our patients who
were mainly Child’s grade A and had biochemically early
stage disease. It could be anticipated that a loss of vitamin A
storage capacity might arise when hepatic stellate cells
(HSCs) undergo transformation into myofibroblasts. How-
ever, Nyberg et al. [21] observed that the number and size of
HSCs and the staining intensity of the retinol binding protein
were actually higher in PBC patients than in controls,
suggesting that low serum vitamin A in PBC is not necessa-
rily a consequence of vitamin A deficiency, but may instead
reflect defective mobilisation of vitamin A from the liver.
Vitamin E was found by Jeffrey et al. [50] to be decreased in
44% of patients with PBC, those with severe cholestasis
being most likely to be affected. Our PBC patients showed no
evidence of significant vitamin E deficiency; this is in
accordance with the findings of Kaplan et al. [20] who found
only 1/52 patients were affected. He concluded that deficien-
cies of fat-soluble vitamins are most likely to be present in
jaundiced patients with long standing severe cholestasis.
Water-soluble vitamin C levels were unaffected in our PBC
group, and patients therefore retain their capacity for regen-
eration of vitamin E by the vitamin C pathway.
Bile acids, which accumulate in the diseased liver and
plasma in PBC, are pro-oxidants causing direct tissue
damage mediated by ROS [40], or indirectly through
activation of tissue resident macrophages [39]. Results from
the rat bile-duct ligation model [8–10] indicate that bile
acid-induced lipid peroxidation may be enhanced in hep-
atocytes in PBC patients presenting with chronic choles-
tasis. In our PBC group, serum total bile acids were
significantly elevated and, not surprisingly, correlated pos-
itively with Ludwig stage. However, we have also shown
for the first time a significant correlation between serum bile
acid levels and the concentration of urinary 8-isoprostane.
Copper-mediated lipid peroxidation, as proposed for Wil-
son’s disease [15], may also contribute to hepatocellular
injury during cholestasis in PBC where copper is known to
accumulate in the liver. In our study, orcein-staining of
copper-associated protein correlated positively with lipid
peroxidation (urinary 8-isoprostane) as well as with hepatic
fibrogenesis (PIIINP) and serum bile acids but negatively
with vitamin A.
Muriel and Suarez [51], in a rat model of acute liver
damage induced by biliary obstruction, demonstrated that
hepatocyte necrosis (as evidenced by serum markers of
tissue damage) preceded lipid peroxidation. This suggests
that the latter is a consequence, rather than the cause, of
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liver injury. The moderate elevation of ALT seen in our PBC
group indicates that, although present, necrosis is not a
major feature in these patients with early stage disease.
Only very limited information is available on the treat-
ment of PBC with antioxidants. One study showed that
administration over a period of 3 months of large oral doses
of vitamin E to PBC patients with very low serum concen-
trations failed to restore levels to normal in the great
majority of cases [50]. In contrast, antioxidant therapy using
a combination treatment of Bio-Antox and Bio-Quinone
Q10 over 3 months has been shown to reduce symptoms of
fatigue and chronic pruritus in PBC patients [52] but no
markers of oxidant stress were studied. Given the very low
intrahepatic levels of glutathione in our patient group, there
may be a case for combining antioxidant therapy with N-
acetylcysteine treatment. In bile duct ligated rats, N-acetyl-
cysteine corrected the reduction in glutathione concentra-
tion, reduced ROS and improved other markers of oxidant
stress [8]. However, in the same rat model, Baron and
Muriel [9] found that although antioxidant treatment
inhibited lipid peroxidation and oxidation of glutathione, it
had no effect on conventional biochemical markers of liver
injury and on liver histology. The authors concluded that
oxidant stress does not play a causative role in this model of
cholestatic liver disease, but is a consequence of bile-salt
induced solubilisation of plasma membranes and cell death.
Therefore, although it is still unclear whether oxidant
stress is involved in the initiation of the disease process in
PBC, it is almost certainly an important factor in disease
progression. Hepatic stellate cells play a key role in the
development of fibrosis, being a major source of collagen
and also of other extracellular matrix proteins in the injured
liver. It has previously been shown that stimulation of lipid
peroxidation or treatment with HNE increases procollagen
mRNA expression in human HSCs [53,54] leading to fibro-
genesis and eventually to cirrhosis. Therefore, oxidant stress
in PBC provides a likely mechanism for disease progression
following the initial immunological insult and leading to the
subsequent development of fibrosis and cirrhosis.
In conclusion, our study shows that oxidant stress,
assessed for the first time in a large group of PBC patients
using a wide range of markers of both oxidant and anti-
oxidant processes in blood and urine, is not just a feature of
late stage decompensated liver disease but is a significant
feature of early PBC. Trials of antioxidant therapy,
adequately monitored, are therefore now indicated to deter-
mine whether early treatment can prevent or slow progres-
sion to cirrhosis and liver failure.
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